Standard BioTools Reports $127M Net Income in Q1, Significantly Narrows Adjusted EBITDA Loss
LAB is trading near its 52-week low of $0.87 (14% above the low).
Summary
Standard BioTools Inc. reported a substantial Q1 net income of $127.07 million, translating to $0.33 EPS, a highly material event for a company with a market capitalization around $382 million. This significant profit is largely attributable to the strategic divestiture of its SomaScan business, as detailed in the company's recent 10-K filing. Additionally, the company's adjusted EBITDA loss narrowed significantly to -$3.10 million, outperforming analyst expectations of a -$9.77 million loss. Revenue grew 5% year-over-year to $21.10 million, driven by a strong 35% increase in consumables, while operating expenses fell 37% due to prior restructuring efforts. Despite a 33% decline in instrument revenue, the company projects 2026 revenue between $80 million and $85 million and expects to achieve positive adjusted EBITDA exiting 2026. This strong financial performance, particularly the cash infusion from the divestiture, provides substantial balance sheet flexibility and is a major positive catalyst for the stock. Investors will now focus on the company's ability to execute on its path to profitability and its strategic use of capital.
At the time of this announcement, LAB was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $382.2M. The 52-week trading range was $0.87 to $1.72. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.